Analysts Expect Syros Pharmaceuticals Inc (SYRS) to Announce -$0.50 EPS

Equities research analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($0.53) to ($0.44). Syros Pharmaceuticals reported earnings per share of ($0.58) in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The firm is scheduled to issue its next earnings results on Monday, March 11th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.86) per share for the current financial year, with EPS estimates ranging from ($1.92) to ($1.77). For the next year, analysts expect that the business will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.72 million.

A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. BidaskClub raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Cann reaffirmed a “buy” rating and set a $26.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $19.00.

NASDAQ:SYRS opened at $8.06 on Wednesday. Syros Pharmaceuticals has a twelve month low of $6.25 and a twelve month high of $15.88. The company has a market cap of $261.16 million, a price-to-earnings ratio of -3.78 and a beta of 0.78.

Large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $119,000. MetLife Investment Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $134,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after buying an additional 9,691 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $177,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $186,000. 60.74% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: What is a put option?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply